Effect of Exenatide on Liver and Heart Fat and Inflammation

Completed · Phase 4

Conditions studied: Type 2 Diabetes Mellitus

In brief

The purpose of this study is to examine the effect of exenatide on liver and heart (myocardial) fat and inflammation.

Key facts

Study ID

NCT01951651

Run by

Baylor College of Medicine

People needed

24

Starts

2010-04-01

Expected to finish

2013-03-01

Last updated by the study team

2016-05-16

Who can join

Age: 30 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.
• Patients may be of either sex. Female patients must be non-lactating and must either be at least two years post-menopausal, or be using adequate contraceptive precautions.
• Patients must range in age from 30 to 70 years, inclusive.
• Patients must meet the American Diabetes Association (ADA) criteria (ADA 1997 Criteria: fasting plasma glucose greater than or equal to 126 mg/dl) for the diagnosis of type 2 diabetes mellitus.
• Patients must be on diet therapy and/or metformin treatment for type 2 diabetes (stable dose)and have a fasting plasma glucose concentration between 126 and 260 mg/dl
• Patients must have Hematocrit greater than 34 vol%.
• Subjects whose body weight has been stable over the three months prior to study enrollment will be included.

You may not qualify if…

• Patients must not have type 1 diabetes.
• Patients must not have a fasting plasma glucose greater than 260 mg/dl.
• Patients must not have received a thiazolidinedione for at least 3 months prior to randomization.
• Patients must not be on insulin treatment or have received insulin for more than one week within the previous year prior to entry. Patients should not be on sulfonylureas, sitagliptin, or exenatide treatment.
• Patients taking systemic glucocorticoids or other medications known to affect glucose tolerance are excluded.
• Patients taking medications that affect gastrointestinal motility will be excluded.
• Patients with a history of Congestive Heart Failure, or clinically significant cardiac, liver or kidney disease (creatinine greater than 1.5 mg/dl).

Where it is running

• Baylor College of Medicine — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.